Cardio-oncology & otherCohort study
Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19
- Prospective longitudinal cohort study
- multicentre
- 25 UK centres
Authors' conclusion
Myocardial injury in severe hospitalized COVID-19 survivors is nonprogressive. Medium-term outcomes show a low incidence of major adverse cardiovascular events and improved quality of life.
Study context
- Population
- Hospitalized COVID-19 survivors with myocardial injury (troponin elevation), UK, June 2020 to March 2021338 with 12-month follow-up
- Participants
- 342 survivors
Main finding
As reported in the abstract
Outcomes within 12 months · 12 months
Died
1.2%
New MI, ACS or coronary revascularization
1.8%
New myopericarditis
0.8%
Other CV events requiring hospitalization
3.3%
Observational data: associations, not effects.
Further findings
Cardiac magnetic resonance (CMR) changes · 6 months
- Minor improvement in LVEF (P < 0.001)
- 1.8% ± 1.0%
- Stable RVEF (P = 0.50)
- 0.4% ± 0.8%
- No change in myocardial scar pattern or volume
- P = 0.26
- Pericardial effusions resolved
- 26 of 26
- Pneumonitis resolved
- 95 of 101
- No imaging evidence of continued myocardial inflammation
- 235 had a 6-month CMR
Quality of life (EuroQol-5 Dimension) · 6 months
- Overall improvement in quality of life
- P < 0.001
- 215 with baseline and follow-up surveys
Original publication
Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19. JACC Cardiovasc Imaging. Published 28 August 2024. doi:10.1016/j.jcmg.2024.06.008
Summarised from the published abstract; every number is checked against it